These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23075686)

  • 21. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.
    De Pas T; Giovannini M; Rescigno M; Catania C; Toffalorio F; Spitaleri G; Delmonte A; Barberis M; Spaggiari L; Solli P; Veronesi G; De Braud F
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):432-43. PubMed ID: 22366114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune Therapy.
    Lievense L; Aerts J; Hegmans J
    Adv Exp Med Biol; 2016; 893():59-90. PubMed ID: 26667339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic vaccines in non-small cell lung cancer.
    Socola F; Scherfenberg N; Raez LE
    Immunotargets Ther; 2013; 2():115-24. PubMed ID: 27471692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
    Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MAGE A3 antigen-specific cancer immunotherapeutic.
    Peled N; Oton AB; Hirsch FR; Bunn P
    Immunotherapy; 2009 Jan; 1(1):19-25. PubMed ID: 20635969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy for Lung Cancer.
    Reinmuth N; Reck M
    Oncol Res Treat; 2016; 39(6):360-8. PubMed ID: 27259861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer.
    Adam V; Wauters I; Vansteenkiste J
    Expert Opin Biol Ther; 2014 Mar; 14(3):365-76. PubMed ID: 24456101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
    Yan BD; Cong XF; Zhao SS; Ren M; Liu ZL; Li Z; Chen C; Yang L
    Curr Cancer Drug Targets; 2019; 19(3):199-209. PubMed ID: 29714142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Why has active immunotherapy not worked in lung cancer?
    Thomas A; Giaccone G
    Ann Oncol; 2015 Nov; 26(11):2213-20. PubMed ID: 26232492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
    Robert C; Soria JC; Eggermont AM
    Eur J Cancer; 2013 Sep; 49(14):2968-71. PubMed ID: 23907003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy.
    Gridelli C; Rossi A; Maione P; Ferrara ML; Castaldo V; Sacco PC
    Oncologist; 2009 Sep; 14(9):909-20. PubMed ID: 19726457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Belagenpumatucel-L for the treatment of non-small cell lung cancer.
    Rijavec E; Biello F; Genova C; Barletta G; Maggioni C; Dal Bello MG; Coco S; Truini A; Vanni I; Alama A; Beltramini S; Grassi MA; Boccardo F; Grossi F
    Expert Opin Biol Ther; 2015; 15(9):1371-9. PubMed ID: 26211534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.
    Rijavec E; Genova C; Alama A; Barletta G; Sini C; Pronzato P; Coco S; Dal Bello MG; Savarino G; Truini A; Boccardo F; Grossi F
    Future Oncol; 2014 Jan; 10(1):79-90. PubMed ID: 24328411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for lung cancer.
    Steven A; Fisher SA; Robinson BW
    Respirology; 2016 Jul; 21(5):821-33. PubMed ID: 27101251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel targeted agents for lung cancer.
    West HJ
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S41-6. PubMed ID: 19362946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunotherapies and targeted therapies in medical oncology].
    Rousseau B; Champiat S; Loirat D; Arrondeau J; Lemoine N; Soria JC
    Bull Cancer; 2014 Jan; 101(1):31-9. PubMed ID: 24333964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy in lung cancer.
    Villaruz LC; Kalyan A; Zarour H; Socinski MA
    Transl Lung Cancer Res; 2014 Feb; 3(1):2-14. PubMed ID: 25806276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.